---
title: "FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284957548.md"
description: "FibroBiologics, Inc. (FBLG) has raised concerns about its ability to continue as a going concern due to ongoing operating losses and negative cash flows. The company relies on uncertain future financing, which may impact its share price and limit capital access. This situation could lead to program cuts and loss of investor capital. Despite these challenges, the average stock price target for FBLG is $19.00, suggesting a potential upside of 1,201.37%."
datetime: "2026-05-02T06:01:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284957548.md)
  - [en](https://longbridge.com/en/news/284957548.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284957548.md)
---

# FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens

FibroBiologics, Inc. (FBLG) has disclosed a new risk, in the Corporate Activity and Growth category.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

FibroBiologics, Inc. faces substantial doubt about its ability to continue as a going concern, given recurring operating losses, negative operating cash flows, and reliance on uncertain future financings and collaborations. This doubt could pressure its share price, constrain access to capital, and limit counterparties’ willingness to enter or maintain business relationships, heightening the risk of further program cuts or loss of investor capital.

The average FBLG stock price target is $19.00, implying 1,201.37% upside potential.

To learn more about FibroBiologics, Inc.’s risk factors, click here.

### Related Stocks

- [FBLG.US](https://longbridge.com/en/quote/FBLG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)